Association among biomarkers, phenotypes, and motor milestones in Chinese patients with 5q spinal muscular atrophy types 1-3 (vol 15, 1382410, 2024)

被引：0
|
作者：
Ouyang, Shijia [1 ]
Peng, Xiaoyin [2 ]
Huang, Wenchen [1 ]
Bai, Jinli [1 ]
Wang, Hong [1 ]
Jin, Yuwei [1 ]
Jiao, Hui [2 ]
Wei, Maoti [3 ]
Ge, Xiushan [2 ]
Song, Fang [1 ]
Qu, Yujin [1 ]
机构：
[1] Capital Inst Pediat, Dept Med Genet, Beijing, Peoples R China
[2] Childrens Hosp, Capital Inst Pediat, Dept Neurol, Beijing, Peoples R China
[3] TEDA Int Cardiovasc Hosp, Ctr Clin Epidemiol, Tianjin, Peoples R China
来源：
FRONTIERS IN NEUROLOGY | 2024年 / 15卷
关键词：
spinal muscular atrophy; biomarkers; severity; motor milestones; survival;
D O I：
10.3389/fneur.2024.1512459
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 7 条
  • [1] Association among biomarkers, phenotypes, and motor milestones in Chinese patients with 5q spinal muscular atrophy types 1-3
    Ouyang, Shijia
    Peng, Xiaoyin
    Huang, Wenchen
    Bai, Jinli
    Wang, Hong
    Jin, Yuwei
    Jiao, Hui
    Wei, Maoti
    Ge, Xiushan
    Song, Fang
    Qu, Yujin
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [2] Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy
    Vazquez-Costa, Juan F.
    Povedano, Monica
    Nascimiento-Osorio, Andres E.
    Moreno Escribano, Antonio
    Kapetanovic Garcia, Solange
    Dominguez, Raul
    Exposito, Jessica M.
    Gonzalez, Laura
    Marco, Carla
    Medina Castillo, Julita
    Muelas, Nuria
    Natera de Benito, Daniel
    Nungo Garzon, Nancy Carolina
    Pitarch Castellano, Inmaculada
    Sevilla, Teresa
    Hervas, David
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (12) : 3666 - 3675
  • [3] COST-EFFECTIVENESS OF RISDIPLAM FOR PATIENTS WITH TYPES 1-3 SPINAL MUSCULAR ATROPHY (SMA) IN FRANCECOST-EFFECTIVENESS OF RISDIPLAM FOR PATIENTSWITH TYPES 1-3 SPINAL MUSCULAR ATROPHY (SMA) IN FRANCE
    Boussahoua, M.
    Sutherland, C. S.
    Aponte, Ribero, V
    Enache, R.
    Le Lay, K.
    Le Dissez, C.
    Chevalier, J.
    VALUE IN HEALTH, 2022, 25 (12) : S87 - S87
  • [4] Respiratory outcomes before and after the introduction of nusinersen in patients with spinal muscular atrophy (Types 1-3)
    Gonski, K.
    Chuang, S.
    Teng, A.
    Thambipillay, G.
    Farrar, M.
    Menezes, M.
    Fitzgerald, D.
    RESPIROLOGY, 2022, 27 : 63 - 63
  • [5] Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1-3 patients treated with nusinersen
    Simic, Goran
    Vukic, Vana
    Babic, Marija
    Banovic, Maria
    Berecic, Ivana
    Spanic, Ena
    Zubcic, Klara
    Golubic, Anja Tea
    Kutija, Marija Barisic
    Sorgic, Ana Merkler
    Vogrinc, Zeljka
    Lehman, Ivan
    Hof, Patrick R.
    Sertic, Jadranka
    Barisic, Nina
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (03)
  • [6] Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy
    Guenther, Rene
    Wurster, Claudia Diana
    Cordts, Isabell
    Koch, Jan Christoph
    Kamm, Christoph
    Petzold, Daniel
    Aust, Elisa
    Deschauer, Marcus
    Lingor, Paul
    Ludolph, Albert Christian
    Hermann, Andreas
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [7] Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3 The Phase 2 TOPAZ Study (vol 102, e209151, 2024)
    Crawford, Thomas O.
    Darras, Basil T.
    Day, John W.
    Young, Sally Dunaway
    Duong, Tina
    Nelson, Leslie L.
    Barrett, Doreen
    Song, Guochen
    Bilic, Sanela
    Cote, Shaun
    Sadanowicz, Mara
    Iarrobino, Ryan
    Xu, Tiina J.
    O'Neil, Janet
    Rossello, Jose
    Place, Amy
    Kertesz, Nathalie
    Nomikos, George
    Chyung, Yung
    NEUROLOGY, 2024, 103 (01)
1